Sanofi
CIK: 0001121404
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect494.8K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect178K shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Conversion(C)Indirect782.9K shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Purchase(P)Indirect300K shares at avg. $17.00$5.1M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 494,800 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 177,978 | - | $0 | Indirect |
| Aug 6, 2026 |  ATTO Attovia Therapeutics, Inc. | Conversion(C) | 782,855 | - | $0 | Indirect |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Purchase(P) | 300,000 | $17.00 | $5,100,000 | Indirect |
1-4 of 4 transactions
About Sanofi
Sanofi (SEC CIK 0001121404) files insider reports with the SEC as 10% Owner of Latigo Biotherapeutics, Inc. (LTGO) and 10% Owner of Attovia Therapeutics, Inc. (ATTO).
Signal8 holds 4 ownership filings by Sanofi (2 Form 3, 2 Form 4), filed between Aug 4, 2026 and Aug 12, 2026. Those filings report 4 transactions, from Aug 6, 2026 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Sanofi's filings is in PARIS.
Recent filings by Sanofi
Other insiders filing for Latigo Biotherapeutics, Inc. (LTGO)
- 5AM Ventures VI, L.P., 10% Owner
- Westlake BioPartners Fund I, L.P., 10% Owner
- Foresite Capital Management V, LLC, 10% Owner
- SMITH TODD N, Director
- Tananbaum James B., Director
- SEIDENBERG BETH C, Director